Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Operating Expenses (2021 - 2025)

Historic Operating Expenses for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$16.6 million.

  • ProQR Therapeutics' Operating Expenses fell 1904.26% to -$16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.0 million, marking a year-over-year increase of 820.92%. This contributed to the annual value of $54.1 million for FY2024, which is 2093.01% up from last year.
  • According to the latest figures from Q3 2025, ProQR Therapeutics' Operating Expenses is -$16.6 million, which was down 1904.26% from -$18.4 million recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics' Operating Expenses registered a high of $127.9 million during Q4 2022, and its lowest value of -$20.9 million during Q3 2022.
  • For the 5-year period, ProQR Therapeutics' Operating Expenses averaged around $2.3 million, with its median value being -$14.8 million (2021).
  • Per our database at Business Quant, ProQR Therapeutics' Operating Expenses skyrocketed by 72911.55% in 2022 and then crashed by 6950.3% in 2025.
  • ProQR Therapeutics' Operating Expenses (Quarter) stood at -$20.3 million in 2021, then skyrocketed by 729.12% to $127.9 million in 2022, then crashed by 40.88% to $75.6 million in 2023, then increased by 20.83% to $91.4 million in 2024, then plummeted by 118.17% to -$16.6 million in 2025.
  • Its Operating Expenses stands at -$16.6 million for Q3 2025, versus -$18.4 million for Q2 2025 and -$16.4 million for Q1 2025.